PDF(Pubmed)
Abstract：
This retrospective observational study aimed to investigate the difference in 4-year outcomes of ranibizumab or aflibercept therapy for macular neovascularization (MNV) with high myopia between pathologic myopia (PM) and non-PM. This study was conducted at Kyoto University Hospital and included consecutive treatment-naïve eyes with active myopic MNV, in which a single intravitreal ranibizumab or aflibercept injection was administered, followed by a pro re nata (PRN) regimen for 4 years. Based on the META-PM study classification, eyes were assigned to the non-PM and PM groups. This study analyzed 118 eyes of 118 patients (non-PM group, 19 eyes; PM group, 99 eyes). Baseline, 1-year, and 2-year best-corrected visual acuity (BCVA) were significantly better in the non-PM group (P = 0.02, 0.01, and 0.02, respectively); however, the 3-year and 4-year BCVA were not. The 4-year BCVA course was similar in both groups. However, the total number of injections over 4 years was significantly higher in the non-PM than in the PM group (4.6 ± 2.6 vs. 2.9 ± 2.6, P = 0.001). Four-year BCVA significantly correlated only with baseline BCVA in both non-PM (P = 0.047, β = 0.46) and PM groups (P < 0.001, β = 0.59). In conclusion, over the 4-year observation period, the BCVA course after anti-VEGF therapy for myopic MNV was similar in the eyes with non-PM and those with PM; however, more additional injections in a PRN regimen were required in the eyes with non-PM compared to those with PM. Thus, more frequent and careful follow-up is required for the eyes with non-PM compared with those with PM to maintain long-term BCVA.
摘要：
这项回顾性观察性研究旨在调查雷珠单抗或阿柏西普治疗高度近视黄斑新生血管（MNV）在病理性近视（PM）和非PM之间的4年结局差异。这项研究是在京都大学医院进行的，包括连续治疗的幼稚眼睛患有活动性近视MNV，其中单次玻璃体内注射雷珠单抗或阿柏西普，随后是prorenata（PRN）方案4年。基于META-PM研究分类，将眼睛分为非PM组和PM组.本研究分析了118例患者的118只眼(非PM组，19只眼；PM组，99只眼睛）。基线,1年,非PM组的最佳矫正视力（BCVA）和2年最佳矫正视力（BCVA）明显更好（分别为P=0.02、0.01和0.02）；然而，3年和4年BCVA没有。两组的4年BCVA课程相似。然而,非PM组的4年注射总数显着高于PM组（4.6±2.6vs.2.9±2.6，P=0.001）。在非PM组（P=0.047，β=0.46）和PM组（P<0.001，β=0.59）中，四年BCVA仅与基线BCVA显着相关。总之,在4年的观察期内,对近视MNV进行抗VEGF治疗后，非PM和PM患者的BCVA病程相似；然而，与PM患者相比,非PM患者需要在PRN方案中更多的额外注射.因此，与非PM患者相比，非PM患者需要更频繁，更仔细的随访以维持长期BCVA。
